Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study

The induction therapy containing ixazomib, an oral proteasome inhibitor, has shown favorable efficacy and safety in clinical trials, but its experience in real-life remains limited. In routine practice, few patients received ixazomib-based induction therapy due to reasons including (1) patients’ pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing, Bao, Li, Xia, Zhongjun, Wang, Sili, Zhou, Xin, Ding, Kaiyang, Zhang, Wenhao, Yang, Wei, Li, Bingzong, Fu, Chengcheng, Chen, Bing, Hua, Luoming, Wang, Liang, Luo, Jun, Yang, Yang, Xu, Tianhong, Wang, Weida, Huang, Yun, Wu, Guolin, Liu, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474576/
https://www.ncbi.nlm.nih.gov/pubmed/32892275
http://dx.doi.org/10.1007/s00277-020-04234-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474576/
https://www.ncbi.nlm.nih.gov/pubmed/32892275
http://dx.doi.org/10.1007/s00277-020-04234-9

Ejemplares similares